assessment of the prognostic value of the ca 125 modeled
play

Assessment of The Prognostic Value Of The CA-125 Modeled Kinetic - PowerPoint PPT Presentation

Sep 27, 2022 •190 likes •251 views

Assessment of The Prognostic Value Of The CA-125 Modeled Kinetic Parameter KELIM in GOG-0262 and MITO-7 trials. Benoit You MD PhD For the GINECO-GINEGEPS. 1. Univ Lyon ; Universit Claude Bernard Lyon 1 ; Facult de mdecine Lyon-Sud ; EMR

  1. Assessment of The Prognostic Value Of The CA-125 Modeled Kinetic Parameter KELIM in GOG-0262 and MITO-7 trials. Benoit You MD PhD For the GINECO-GINEGEPS. 1. Univ Lyon ; Université Claude Bernard Lyon 1 ; Faculté de médecine Lyon-Sud ; EMR UCBL/HCL 3738 ; Lyon ; France ; 2. Medical Oncology ; Institut de Cancérologie des Hospices Civils de Lyon (IC- HCL) ; CITOHL ; Centre Hospitalier Lyon-Sud ; Lyon ; France; 3. GINECO-GINEGEPS

  2. Background • N eed for early predictors of treatment efficacy in ovarian cancer patients treated by chemotherapy +/- targeted agents CA-125 based Rustin criteria is commonly used to predict • treatment efficacy during phase II trials J Clin Oncol 1996; 14:1545–1551 Ä the actual value was recently questionned ! JNCI 2011; 103: 1338–1342 Mathematical modeling of longitudinal CA-125 kinetics • may help analyze individual CA-125 decline profiles The CA-125 elimination modeled parameter KELIM was a • significant independent prognostic factor of treatment efficacy in CALYPSO trial (recurrent ovarian cancer patients) Gynecol Oncol. 2013 Aug;130(2):289-94 => Validation of KELIM prognostic factor regarding PFS in independent phase III trial cohorts of patients treated with different first line regimens was warranted B You. Abs 5554 ASCO 2017

  3. Recent data from phase III trials … B You. Abs 5554 ASCO 2017

  4. PFS (months) OS (months) Treatment Favorable KELIM Unfavorable Favorable KELIM Unfavorable KELIM KELIM > 0.059 > 0.059 NR: not <= 0.059 <= 0.059 reached AGO/OVAR9 CP 25.6 11.4 59.5 36.6 CP + Gemcitabine 21.9 11.2 NR, >70 38.7 AGO/OVAR7 CP 28.3 12.8 NR, > 60 45.5 CP + topotecan 19.5 10.2 NR, > 60 31.6 ICON7 CP 25.2 8.8 NR, > 60 36.2 CP + bevacizumab 20.7 13.9 65.0 38.7 AGO-OVAR 9 ICON 7 AGO-OVAR 9 AGO-OVAR 7 N=1386 patients N=1285 patients N=189 patients B You. Abs 5554 ASCO 2017

  5. Hypotheses • KELIM, estimated in the first 100 days during first line chemotherapy Ä Discriminates 2 prognostic populations of ovarian cancer patients whatever received treatments Median survival of 35 months vs > 60 months • Marker of chemo-resistance ? • What would be the impact of administration schedules on KELIM ? • Role for dose-dense chemo in unfavorable KELIM patients ? B You. Proposal GCIG

  6. Proposal • MITO-7 trial : Carboplatin AUC6 + paclitaxel 175 Impact of mg/m2 Q3W vs chemotherapy carboplatin AUC2 + paclitaxel 60 administration mg/m2 Q1W schedules and doses on KELIM ? Would dose-dense paclitaxel • GOG-0262: counterbalance Carboplatin AUC6 + paclitaxel 175 unfavorable KELIM ? mg/m2 Q3W vs carboplatin AUC6 Q3W + paclitaxel 80 mg/m2 Q1W B You. Proposal GCIG

Download Presentation
Download Policy: The content available on the website is offered to you 'AS IS' for your personal information and use only. It cannot be commercialized, licensed, or distributed on other websites without prior consent from the author. To download a presentation, simply click this link. If you encounter any difficulties during the download process, it's possible that the publisher has removed the file from their server.

Recommend

An integrated modeled and measurement-based assessment of particle number concentrations from a

An integrated modeled and measurement-based assessment of particle number concentrations from a

FAA CENTER OF EXCELLENCE FOR ALTERNATIVE JET FUELS &amp; ENVIRONMENT An integrated modeled and measurement-based assessment of particle number concentrations from a major US airport Chowdhury G. Moniruzzman 1 , Kevin Lane 2 , Jonathan I. Levy 2 ,

407 views • 16 slides
A Metric for the Prognostic Outreach of Scenarios Learning from the Past to Establish a

A Metric for the Prognostic Outreach of Scenarios Learning from the Past to Establish a

Spatio-Temporal Uncertainty Assessment of GHG Emission Inventories with the Specific Focus on Austria and Ukraine: Learning in Space and Time and into the Future A Metric for the Prognostic Outreach of Scenarios Learning from the Past to

514 views • 34 slides
PROGNOSTIC AND PREDICTIVE BIOMARKERS IN NSCLC Federico Cappuzzo Istituto Toscano Tumori

PROGNOSTIC AND PREDICTIVE BIOMARKERS IN NSCLC Federico Cappuzzo Istituto Toscano Tumori

PROGNOSTIC AND PREDICTIVE BIOMARKERS IN NSCLC Federico Cappuzzo Istituto Toscano Tumori Ospedale Civile-Livorno Italy Prognostic versus predictive Prognostic: In presence of the biomarker patient outcome independent of the

398 views • 36 slides
Prognostic Markers can Guide Therapy? Alan K Burnett School of Medicine Cardiff University NO

Prognostic Markers can Guide Therapy? Alan K Burnett School of Medicine Cardiff University NO

Prognostic Markers can Guide Therapy? Alan K Burnett School of Medicine Cardiff University NO (t yet) Prognostic is Not Necessarily Predictive Prognostic Factor Evolution Multivariate analysis Validation on independent data Test

483 views • 36 slides
The ELN risk classification has prognostic relevance also in

The ELN risk classification has prognostic relevance also in

The ELN risk classification has prognostic relevance also in elderly patients with secondary acute myeloid leukemia and may support treatment decisions. A

389 views • 17 slides
Cancer staging in 2022 Brian OSullivan, MD Chair, Prognostic Factors Task Force, UICC TNM

Cancer staging in 2022 Brian OSullivan, MD Chair, Prognostic Factors Task Force, UICC TNM

Union for International Cancer Control Cancer stage: a neglected cornerstone of cancer control Cancer staging in 2022 Brian OSullivan, MD Chair, Prognostic Factors Task Force, UICC TNM Prognostic Factors Core Committee August 28, 2012

239 views • 19 slides
Identification of Prognostic Genes, Combining Information Across Different Institutions and

Identification of Prognostic Genes, Combining Information Across Different Institutions and

Identification of Prognostic Genes, Combining Information Across Different Institutions and Oligonucleotide Arrays Jeffrey S. Morris , Guosheng Yin, Keith Baggerly, Chunlei Wu, and Li Zhang UT MD Anderson Cancer Center Department of

362 views • 32 slides
Liquid biopsies as prognostic and predictive biomarkers; ready for the clinic? AR-V7

Liquid biopsies as prognostic and predictive biomarkers; ready for the clinic? AR-V7

Liquid biopsies as prognostic and predictive biomarkers; ready for the clinic? AR-V7 expression in CTCs from patients with castration- resistant prostate cancer &amp; Feasibility studies of circulation tumor DNA analysis John W. M.

575 views • 34 slides
Prognostic and Predictive Markers: Whats the difference? &amp; Why should I care? Susan G.

Prognostic and Predictive Markers: Whats the difference? &amp; Why should I care? Susan G.

CANSSI Biomarker and Drug Co-Development Workshop Prognostic and Predictive Markers: Whats the difference? &amp; Why should I care? Susan G. Hilsenbeck, PhD Division of Biostatistics Smith Breast Center and Duncan Cancer Center Baylor

605 views • 47 slides
Question: Is there a role of biologic prognostic markers in the treatment of CLL? YES: Robin Foa

Question: Is there a role of biologic prognostic markers in the treatment of CLL? YES: Robin Foa

Question: Is there a role of biologic prognostic markers in the treatment of CLL? YES: Robin Foa NO: Kanti Rai Kanti R. Rai 1 1 Relevant References Hallek et al, Blood 2008, New Guidelines. Weidra et al, JCO 2009, Beta-2, Age

380 views • 15 slides
Reproducibility and Cross-study Replicability of Prognostic Signatures from High Throughput

Reproducibility and Cross-study Replicability of Prognostic Signatures from High Throughput

Reproducibility and Cross-study Replicability of Prognostic Signatures from High Throughput Genomic Data giovanni parmigiani@dfci.harvard.edu 2014 Rutgers Statistics Symposium signatures and prognosis Sorlie PNAS 03 CuratedOvarianData

275 views • 24 slides
Transcatheter Aortic Valve Implantation: Insights on Prognostic Factors and Valve Durability

Transcatheter Aortic Valve Implantation: Insights on Prognostic Factors and Valve Durability

Long-Term Outcomes Following Transcatheter Aortic Valve Implantation: Insights on Prognostic Factors and Valve Durability from the Canadian Multicenter Experience Josep Rods-Cabau, M.D. Quebec Heart &amp; Lung Institute, Laval University

581 views • 31 slides
Identifying High-Risk Patients in Follicular Lymphoma with a new prognostic score Federico

Identifying High-Risk Patients in Follicular Lymphoma with a new prognostic score Federico

Identifying High-Risk Patients in Follicular Lymphoma with a new prognostic score Federico Mattiello* BBS Seminar, 1 November 2019, Basel *on behalf of the EDIS-NHL team GALLIUM clinical trial improved outcomes med.PFS 8 years with

388 views • 17 slides
Chapter 5 A Prognostic Factor Analysis based on Cox PH Model Example: CNS lymphoma data The data

Chapter 5 A Prognostic Factor Analysis based on Cox PH Model Example: CNS lymphoma data The data

Chapter 5 A Prognostic Factor Analysis based on Cox PH Model Example: CNS lymphoma data The data result from an observational clinical study conducted at Oregon Health Sciences University (OHSU). Fifty-eight non-AIDS patients with central

303 views • 15 slides
Dynamic Thresholds and a Summary ROC Curve: Assessing the Prognostic Accuracy of Longitudinal

Dynamic Thresholds and a Summary ROC Curve: Assessing the Prognostic Accuracy of Longitudinal

Dynamic Thresholds and a Summary ROC Curve: Assessing the Prognostic Accuracy of Longitudinal Markers Paramita Saha Chaudhuri Department of Biostatistics and Bioinformatics Duke University School of Medicine October 6, 2012 1 AISC, 2012

1.07k views • 35 slides
Prognostic factors in MDS Esther N Oliva Grande Ospedale Metropolitano BMM Reggio Calabria,

Prognostic factors in MDS Esther N Oliva Grande Ospedale Metropolitano BMM Reggio Calabria,

Myelodysplastic syndromes: chaos and order Prognostic factors in MDS Esther N Oliva Grande Ospedale Metropolitano BMM Reggio Calabria, Italy Prognosis linked to treatment 4 Age, comorbidites, cytogenetics (genetics) and blasts, as well as the

364 views • 35 slides
Prognostication 4 1 4/9/19 Prognostication Mrs. Alvarez is a 79 yo woman with COPD, Why

Prognostication 4 1 4/9/19 Prognostication Mrs. Alvarez is a 79 yo woman with COPD, Why

4/9/19 Clinical Issues in Geriatrics for Primary Care I have no financial Di Disclosures Practice disclosures to report. Brook Calton, MD, MHS Assistant Professor of Clinical Medicine Division of Palliative Medicine University of

179 views • 14 slides
Conflict of Interest HRT: New Evidence on a Old Topic Conflict of Interest None Off

Conflict of Interest HRT: New Evidence on a Old Topic Conflict of Interest None Off

10/19/2018 Conflict of Interest HRT: New Evidence on a Old Topic Conflict of Interest None Off label drug use Mirena IUD Gabapentin Marcelle I. Cedars, M.D. Effexor Professor and Director Division of Reproductive

389 views • 13 slides
but also prof. dr. Andrej Filipi , IJS, UNG prof. dr. Borut P . Kerevan , Uni Lj, IJS Dejan

but also prof. dr. Andrej Filipi , IJS, UNG prof. dr. Borut P . Kerevan , Uni Lj, IJS Dejan

Joef Stefan Institute SLING - Slovenian Supercomputing Network Site Report for NDGF all Hands 2017 Barbara Kroovec Jan Jona Javorek http://www.arnes.si http://www.ijs.si/ barbara.krasovec@arnes.si http://www.sling.si/

748 views • 25 slides
Via Imam al-Sadiq (also reported from the Prophet) - 1 Root word- aba, only occurs once in

Via Imam al-Sadiq (also reported from the Prophet) - 1 Root word- aba, only occurs once in

Dua Makarim al-Akhlaq- The Supplication on Noble Character and Acts Pleasing to God Dars 1 Summary: Vinay Khetia What are Islamic Ethics? Science of ilm al-akhlaq - seeks to know which state of mind/being must be nurtured and which actions

215 views • 4 slides
Appropriate validation of (predictive) biomarkers Elise C. Kohn, MD Gynecologic Cancer

Appropriate validation of (predictive) biomarkers Elise C. Kohn, MD Gynecologic Cancer

Gynecologic Cancer InterGroup Translational Research Brainstorming October 2016 Lisbon Appropriate validation of (predictive) biomarkers Elise C. Kohn, MD Gynecologic Cancer Therapeutics CTEP/DCTD/NCI-US BEST

307 views • 12 slides
Achieving Performance Isolation with Lightweight Co-Kernels Jiannan Ouyang , Brian Kocoloski, John

Achieving Performance Isolation with Lightweight Co-Kernels Jiannan Ouyang , Brian Kocoloski, John

Achieving Performance Isolation with Lightweight Co-Kernels Jiannan Ouyang , Brian Kocoloski, John Lange The Prognostic Lab @ University of Pittsburgh Kevin Pedretti Sandia National Laboratories HPDC 2015 HPC Architecture Traditional In Situ

280 views • 24 slides
for Composition of Applications Brian Kocoloski Hasan Abbasi David Bernholdt Jack Lange Terry

for Composition of Applications Brian Kocoloski Hasan Abbasi David Bernholdt Jack Lange Terry

System-Level Support for Composition of Applications Brian Kocoloski Hasan Abbasi David Bernholdt Jack Lange Terry Jones Jai Dayal Noah Evans Jay Lofstead Michael Lang Kevin Pedretti Patrick Bridges The Hobbes Exascale Operating

547 views • 21 slides
Diurnal Cycle of Shallow Cumulus over Land Geert Lenderink, A. Pier Siebesma (siebesma@knmi.nl)

Diurnal Cycle of Shallow Cumulus over Land Geert Lenderink, A. Pier Siebesma (siebesma@knmi.nl)

Diurnal Cycle of Shallow Cumulus over Land Geert Lenderink, A. Pier Siebesma (siebesma@knmi.nl) Questions: Do models reproduce correct timing? Do scaling laws still apply? How is subcloud layer affected by cu? Set up of the case.

514 views • 23 slides

More recommend